March 4, 2024 01:57 PM EST
Deals
Pharma

San­doz com­pletes $170M buy of Lu­cen­tis biosim­i­lar from Co­herus Bio­Sciences

Katherine Lewin

News Reporter

San­doz’s $170 mil­lion cash deal to buy oph­thal­mol­o­gy biosim­i­lar Cimer­li from Co­herus Bio­Sciences has com­plet­ed ear­ly fol­low­ing its an­nounce­ment in Jan­u­ary. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times